Oakland, CA, United States of America

Matthew Volgraf

USPTO Granted Patents = 19 

Average Co-Inventor Count = 6.8

ph-index = 2

Forward Citations = 13(Granted Patents)


Location History:

  • Oakland, CA (US) (2012 - 2020)
  • South San Francisco, CA (US) (2019 - 2023)

Company Filing History:


Years Active: 2012-2025

Loading Chart...
19 patents (USPTO):

Title: Unveiling the Innovations of Matthew Volgraf: Pioneer of Pharmaceuticals

Introduction:

Matthew Volgraf, a brilliant inventor hailing from Oakland, California, has made significant contributions to the field of pharmaceuticals with a total of 17 patents under his belt.

Latest Patents:

Among his groundbreaking inventions are the "Oxadiazole transient receptor potential channel inhibitors," which offer novel methods for treating diseases mediated by TRPA1, such as pain. Additionally, his work on "Sulfonylurea compounds as inhibitors of interleukin-1 activity" showcases his innovative approach in targeting disorders responsive to cytokine modulation.

Career Highlights:

Matthew Volgraf has left an indelible mark on renowned companies such as Genentech, Inc., and the esteemed University of California. His expertise and dedication have led to the development of transformative pharmaceutical solutions that have the potential to revolutionize the medical landscape.

Collaborations:

Throughout his illustrious career, Matthew Volgraf has collaborated with esteemed professionals in the field, including the likes of Elisia Villemure and Dirk Trauner. These partnerships have further enriched his innovative endeavors and solidified his reputation as a pioneer in the pharmaceutical industry.

Conclusion:

In conclusion, Matthew Volgraf epitomizes the essence of innovation and ingenuity in the realm of pharmaceutical research. His relentless pursuit of excellence and groundbreaking discoveries continue to shape the future of medicine, offering hope and relief to those in need.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…